← Al het nieuws

Temple Therapeutics Published Key Mechanism Data for Evitar™

Temple Therapeutics, a clinical stage biopharmaceutical company focused in developing therapeutics for fibrosis and oncology, announces the publication of groundbreaking mechanistic data for Evitar™ in Reproductive Sciences, a peer reviewed journal of the Society of Reproductive Investigations.  The publication includes data to support a credible hypothesis for Evitar™’s mechanism of action advanced by Temple’s CSO, Dr. Lynne Robertson.  This hypothesis proposes that novel drug candidate Evitar™  modulates key upstream inflammatory mediators, such Hypoxia Inducible Factor 1 Alpha (HIF1-α) and Type 1 Collagen, which, when left unchecked, promote abnormal healing and tissue fibrosis.

Additionally, data from the Evitar™ proof-of-concept randomized clinical trial was recently accepted for presentation at 47th Annual Global Congress of AAGL (American Association of Gynecologic Laparoscopists) scheduled for November 2018.

“Post-surgical adhesions are broadly recognized as the single greatest cause of surgical complications. Moreover, they have evaded effective intervention, until now” comments Sanj Singh, CEO of Temple.  “These mechanism-of-action and randomized clinical trial data speak to the underlying biology driving surgical adhesions.  We are pleased to note the publication’s acceptance in Reproductive Sciences, a high-impact, peer-reviewed journal.  This publication and the forthcoming AAGL presentation further support the Evitar™ value proposition.  Adhesion prevention is only the beginning.  However, it provides a relevant model to further the study of both fibrosis and cancer pathophysiology.  Temple is leveraging these insights to further its pipeline of first-in-class therapeutics for the management of adhesions, endometriosis and ovarian cancer.”

Robertson, L., King, N., Diamond, M., & Saed, G., Evitar™(l-Alanyl-l-Glutamine) Regulates Key Signaling Molecules in the Pathogenesis of Postoperative Tissue Fibrosis, Reproductive Sciences, September 5, 2018

Source: Temple Therapeutics